Time is on Novartis Side in Alcon Bid
Novartiss bet that with time it would win over Alcon Inc.s shareholders seems to be paying off. Since the Swiss pharma giant bought a majority stake in the eye-care firm earlier this year, resistance from Alcons minority shareholders to Novartiss off...